{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"42.440","rs_stock_flag":false,"fiscal_year_end":"2025年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"113,926,864","primaryexch":"香港交易所","ric":"2561.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":null,"inline_upper_strike_price":"","sedol":"BPCXBJ7","am":"3.75","iv":"","ew_strike":"","as":"41.880","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"41.680","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"100","update_time":"2025-09-28 00:06:03.0","lo52":"39.250","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"付山","underlying_ric":"2561.HK","hi52":"69.150","issuer_name":"維昇藥業 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日15:48","aum_date":"","lo":"41.100","mkt_cap":"4.74","f_aum_hkd":null,"ew_sub_per_to":"","ls":"41.680","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"+0.020","aum":"","issued_shares_class_B":null,"vo":"89.38","secondary_listing_flag":false,"listing_date":"2025年3月21日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"維昇藥業 - B","nm_s":"維昇藥業－Ｂ","sym":"2561","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.020","strike_price":"","summary":"維昇藥業是一家主要從事開發並商業化顛覆式內分泌療法的投資控股公司。該公司的主要在研產品包括隆培促生長素、那韋培肽和帕羅培特立帕肽。隆培促生長素用於治療3至17歲兒童生長激素缺乏症患者。那韋培肽是一款用於治療2至10歲軟骨發育不全兒童患者的疾病修復療法。帕羅培特立帕肽是一款用於治療成人甲狀旁腺功能減退症的治療方法。該公司處於研發後期、產品接近商業化。","op":"41.660","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港銅鑼灣<br/>希慎道33號<br/>利園一期<br/>19樓1919室","pc":"+0.05","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":null,"hdr":false,"launch_date":"","hc":"41.660","isin":"KYG93Y5D1039","moneyness":""}},"qid":"1759074477672"}
